<p>瑞銀集團在其最近向證券交易委員會提交的 13F 表格中表示，在第四季度將其在啓迪醫療系統公司的股份減少了 12.1%。該基金在此期間出售了 56,407 股後，持有該公司 411,329 股股票。截至其最近向證券交易委員會提交的文件，瑞銀集團持有的啓迪醫療系統股份約佔 1.42%，價值 37,937,000 美元。</p>
<ul>
<li>艾利 Lilly 股票上漲：GLP-1 Zepbound 目標睡眠呼吸暫停市場</li>
</ul>
<p>其他幾家大型投資者最近也調整了對該公司的持股。Sanctuary Advisors LLC 在第四季度收購了價值 481,000 美元的啓迪醫療系統新股份。Concurrent Investment Advisors LLC 在第四季度將其在啓迪醫療系統的股份增加了 52.0%。Concurrent Investment Advisors LLC 現在持有 4,815 股該公司股票，價值 444,000 美元，此前在上個季度又購買了 1,647 股。M&amp;T Bank Corp 在第四季度收購了價值 85,871,000 美元的啓迪醫療系統新股份。Universal Beteiligungs und Servicegesellschaft mbH 在第四季度將其在啓迪醫療系統的股份增加了 990.1%。Universal Beteiligungs und Servicegesellschaft mbH 現在持有 38,404 股該公司股票，價值 3,542,000 美元，此前在此期間又購買了 34,881 股。最後，蘇黎世州立銀行在第四季度將其在啓迪醫療系統的股份增加了 5.8%。蘇黎世州立銀行現在持有 9,265 股該公司股票，價值 855,000 美元，此前在上個季度又購買了 507 股。機構投資者持有該公司 94.91% 的股份。</p>
<h2>啓迪醫療系統股票下跌 0.5%</h2>
<p>NYSE:INSP 的股票在週五開盤時為 45.48 美元。啓迪醫療系統公司的 12 個月低點為 44.41 美元，12 個月高點為 161.88 美元。該股票的 50 日移動平均線為 56.01 美元，200 日移動平均線為 78.97 美元。該公司的市值為 13.1 億美元，市盈率為 10.13，PEG 比率為 4.73，貝塔值為 0.83。</p>
<ul>
<li>啓迪醫療上漲 15% 後突破，分析師稱其為買入</li>
</ul>
<p>啓迪醫療系統（NYSE:INSP - 獲取免費報告）最後一次公佈季度財報是在 5 月 4 日，週一。該公司報告季度每股收益為 0.10 美元，超出分析師共識預期的（0.28 美元）0.38 美元。啓迪醫療系統的淨利潤率為 14.33%，股本回報率為 10.35%。該公司在本季度的收入為 2.0458 億美元，而分析師預期為 2.0004 億美元。在去年同期，該公司每股收益為 0.10 美元。啓迪醫療系統的季度收入同比增長 1.6%。啓迪醫療系統已將其 2026 財年的指導目標設定為 0.750-1.250 每股收益。股票研究分析師預計啓迪醫療系統將在當前財年發佈 0.91 的每股收益。</p>
<h2>分析師評級變動</h2>
<p>INSP 最近成為多份分析師報告的主題。美國銀行在週二重申了對啓迪醫療系統的 “中性” 評級，並設定了 53.00 美元的目標價。Zacks Research 在 4 月 14 日的研究報告中將啓迪醫療系統的評級從 “強力買入” 下調至 “持有”。Piper Sandler 在週二將啓迪醫療系統的評級從 “增持” 下調至 “中性”，並將其目標價從 85.00 美元下調至 55.00 美元。摩根大通在週二將啓迪醫療系統的目標價從 67.00 美元下調至 54.00 美元，並對該公司設定了 “中性” 評級。最後，羅伯特·W·貝爾德在週二將啓迪醫療系統的目標價從 63.00 美元下調至 50.00 美元，並對該股票設定了 “中性” 評級。四位股票研究分析師對該股票給予了買入評級，十五位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該公司目前的共識評級為 “持有”，平均目標價為 85.00 美元。</p>
<ul>
<li>小型股是否預示市場下跌？</li>
</ul>
<p><strong>查看我們最新的 INSP 股票報告</strong></p>
<h2>啓迪醫療系統公司簡介</h2>
<p>（免費報告）</p>
<p>啓迪醫療系統公司是一家醫療技術公司，專注於用於治療阻塞性睡眠呼吸暫停（OSA）的可植入神經刺激設備。該公司的旗艦產品，Inspire®系統，通過對舌下神經的定向刺激，保持睡眠期間氣道通暢，為對持續正壓呼吸機（CPAP）設備不耐受或管理不當的患者提供了一種替代療法。</p>
<p>Inspire 系統包括一個可植入的脈衝發生器，一個監測呼吸模式的傳感導線，以及一個激活舌下神經的刺激導線。</p>
<h2>另見</h2>
<ul>
<li>五隻我們更看好的股票，勝過啓迪醫療系統</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUlOU1A?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUlOU1A"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元於啓迪醫療系統嗎？</h2>
<p>在考慮啓迪醫療系統之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買...而啓迪醫療系統並不在名單上。</p>
<p>儘管啓迪醫療目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

啟迪醫療

瑞銀集團

<p>瑞銀集團（UBS Group AG）已將其在啓迪醫療（Inspire Medical Systems, Inc.）的持股比例降低了 12.1%，在第四季度出售了 56,407 股，剩餘持股為 411,329 股，估值約為 3,794 萬美元。其他機構投資者也對其持股進行了調整。啓迪醫療的股票開盤價為 45.48 美元，下跌 0.5%，市值為 13.1 億美元。該公司報告的季度每股收益（EPS）為 0.10 美元，超出預期，並已將 2026 財年的指導目標設定為 0.750-1.250 的每股收益。分析師對該股票的評級意見不一，普遍評級為 “持有”，平均目標價為 85.00 美元</p>

<p>UBS Group AG reduced its position in shares of Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) by 12.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 411,329 shares of the company's stock after selling 56,407 shares during the period. UBS Group AG owned about 1.42% of Inspire Medical Systems worth $37,937,000 as of its most recent filing with the Securities and Exchange Commission.</p>
<div class="lb-trans"><p>瑞銀集團在其最近向證券交易委員會提交的 13F 表格中表示，在第四季度將其在啓迪醫療系統公司的股份減少了 12.1%。該基金在此期間出售了 56,407 股後，持有該公司 411,329 股股票。截至其最近向證券交易委員會提交的文件，瑞銀集團持有的啓迪醫療系統股份約佔 1.42%，價值 37,937,000 美元。</p>
</div><ul>
<li>Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market</li>
</ul>
<div class="lb-trans"><ul>
<li>艾利 Lilly 股票上漲：GLP-1 Zepbound 目標睡眠呼吸暫停市場</li>
</ul>
</div><p>Several other large investors have also recently modified their holdings of the business. Sanctuary Advisors LLC acquired a new stake in Inspire Medical Systems in the fourth quarter valued at $481,000. Concurrent Investment Advisors LLC boosted its stake in shares of Inspire Medical Systems by 52.0% in the 4th quarter. Concurrent Investment Advisors LLC now owns 4,815 shares of the company's stock valued at $444,000 after purchasing an additional 1,647 shares during the last quarter. M&amp;T Bank Corp bought a new stake in shares of Inspire Medical Systems in the 4th quarter valued at $85,871,000. Universal Beteiligungs und Servicegesellschaft mbH increased its position in shares of Inspire Medical Systems by 990.1% during the fourth quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 38,404 shares of the company's stock worth $3,542,000 after buying an additional 34,881 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Inspire Medical Systems by 5.8% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,265 shares of the company's stock worth $855,000 after buying an additional 507 shares during the last quarter. Institutional investors own 94.91% of the company's stock.</p>
<div class="lb-trans"><p>其他幾家大型投資者最近也調整了對該公司的持股。Sanctuary Advisors LLC 在第四季度收購了價值 481,000 美元的啓迪醫療系統新股份。Concurrent Investment Advisors LLC 在第四季度將其在啓迪醫療系統的股份增加了 52.0%。Concurrent Investment Advisors LLC 現在持有 4,815 股該公司股票，價值 444,000 美元，此前在上個季度又購買了 1,647 股。M&amp;T Bank Corp 在第四季度收購了價值 85,871,000 美元的啓迪醫療系統新股份。Universal Beteiligungs und Servicegesellschaft mbH 在第四季度將其在啓迪醫療系統的股份增加了 990.1%。Universal Beteiligungs und Servicegesellschaft mbH 現在持有 38,404 股該公司股票，價值 3,542,000 美元，此前在此期間又購買了 34,881 股。最後，蘇黎世州立銀行在第四季度將其在啓迪醫療系統的股份增加了 5.8%。蘇黎世州立銀行現在持有 9,265 股該公司股票，價值 855,000 美元，此前在上個季度又購買了 507 股。機構投資者持有該公司 94.91% 的股份。</p>
</div><h2>Inspire Medical Systems Stock Down 0.5%</h2>
<div class="lb-trans"><h2>啓迪醫療系統股票下跌 0.5%</h2>
</div><p>Shares of NYSE:INSP opened at $45.48 on Friday. Inspire Medical Systems, Inc. has a twelve month low of $44.41 and a twelve month high of $161.88. The stock's 50 day moving average is $56.01 and its 200-day moving average is $78.97. The firm has a market capitalization of $1.31 billion, a price-to-earnings ratio of 10.13, a PEG ratio of 4.73 and a beta of 0.83.</p>
<div class="lb-trans"><p>NYSE:INSP 的股票在週五開盤時為 45.48 美元。啓迪醫療系統公司的 12 個月低點為 44.41 美元，12 個月高點為 161.88 美元。該股票的 50 日移動平均線為 56.01 美元，200 日移動平均線為 78.97 美元。該公司的市值為 13.1 億美元，市盈率為 10.13，PEG 比率為 4.73，貝塔值為 0.83。</p>
</div><ul>
<li>Inspire Medical Up 15% After Breakout, Analysts Say It's A Buy</li>
</ul>
<div class="lb-trans"><ul>
<li>啓迪醫療上漲 15% 後突破，分析師稱其為買入</li>
</ul>
</div><p>Inspire Medical Systems (NYSE:INSP - Get Free Report) last announced its quarterly earnings results on Monday, May 4th. The company reported $0.10 EPS for the quarter, beating analysts' consensus estimates of ($0.28) by $0.38. Inspire Medical Systems had a net margin of 14.33% and a return on equity of 10.35%. The business had revenue of $204.58 million during the quarter, compared to analyst estimates of $200.04 million. During the same quarter in the previous year, the business posted $0.10 EPS. Inspire Medical Systems's quarterly revenue was up 1.6% on a year-over-year basis. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. Equities research analysts anticipate that Inspire Medical Systems, Inc. will post 0.91 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>啓迪醫療系統（NYSE:INSP - 獲取免費報告）最後一次公佈季度財報是在 5 月 4 日，週一。該公司報告季度每股收益為 0.10 美元，超出分析師共識預期的（0.28 美元）0.38 美元。啓迪醫療系統的淨利潤率為 14.33%，股本回報率為 10.35%。該公司在本季度的收入為 2.0458 億美元，而分析師預期為 2.0004 億美元。在去年同期，該公司每股收益為 0.10 美元。啓迪醫療系統的季度收入同比增長 1.6%。啓迪醫療系統已將其 2026 財年的指導目標設定為 0.750-1.250 每股收益。股票研究分析師預計啓迪醫療系統將在當前財年發佈 0.91 的每股收益。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><p>INSP has been the subject of a number of recent analyst reports. Bank of America reiterated a &#34;neutral&#34; rating and set a $53.00 price target on shares of Inspire Medical Systems in a report on Tuesday. Zacks Research lowered Inspire Medical Systems from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Tuesday, April 14th. Piper Sandler downgraded Inspire Medical Systems from an &#34;overweight&#34; rating to a &#34;neutral&#34; rating and lowered their target price for the stock from $85.00 to $55.00 in a report on Tuesday. JPMorgan Chase &amp; Co. lowered their price objective on shares of Inspire Medical Systems from $67.00 to $54.00 and set a &#34;neutral&#34; rating for the company in a research note on Tuesday. Finally, Robert W. Baird dropped their target price on shares of Inspire Medical Systems from $63.00 to $50.00 and set a &#34;neutral&#34; rating on the stock in a research report on Tuesday. Four equities research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of &#34;Hold&#34; and an average target price of $85.00.</p>
<div class="lb-trans"><p>INSP 最近成為多份分析師報告的主題。美國銀行在週二重申了對啓迪醫療系統的 “中性” 評級，並設定了 53.00 美元的目標價。Zacks Research 在 4 月 14 日的研究報告中將啓迪醫療系統的評級從 “強力買入” 下調至 “持有”。Piper Sandler 在週二將啓迪醫療系統的評級從 “增持” 下調至 “中性”，並將其目標價從 85.00 美元下調至 55.00 美元。摩根大通在週二將啓迪醫療系統的目標價從 67.00 美元下調至 54.00 美元，並對該公司設定了 “中性” 評級。最後，羅伯特·W·貝爾德在週二將啓迪醫療系統的目標價從 63.00 美元下調至 50.00 美元，並對該股票設定了 “中性” 評級。四位股票研究分析師對該股票給予了買入評級，十五位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該公司目前的共識評級為 “持有”，平均目標價為 85.00 美元。</p>
</div><ul>
<li>Are Small Caps a Harbinger of Market Declines?</li>
</ul>
<div class="lb-trans"><ul>
<li>小型股是否預示市場下跌？</li>
</ul>
</div><p><strong>Check Out Our Latest Stock Report on INSP</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 INSP 股票報告</strong></p>
</div><h2>Inspire Medical Systems Company Profile</h2>
<div class="lb-trans"><h2>啓迪醫療系統公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company's flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.</p>
<div class="lb-trans"><p>啓迪醫療系統公司是一家醫療技術公司，專注於用於治療阻塞性睡眠呼吸暫停（OSA）的可植入神經刺激設備。該公司的旗艦產品，Inspire®系統，通過對舌下神經的定向刺激，保持睡眠期間氣道通暢，為對持續正壓呼吸機（CPAP）設備不耐受或管理不當的患者提供了一種替代療法。</p>
</div><p>The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.</p>
<div class="lb-trans"><p>Inspire 系統包括一個可植入的脈衝發生器，一個監測呼吸模式的傳感導線，以及一個激活舌下神經的刺激導線。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Inspire Medical Systems</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過啓迪醫療系統</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUlOU1A" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=INSP"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Inspire Medical Systems Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元於啓迪醫療系統嗎？</h2>
</div><p>Before you consider Inspire Medical Systems, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮啓迪醫療系統之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inspire Medical Systems wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買...而啓迪醫療系統並不在名單上。</p>
</div><p>While Inspire Medical Systems currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>儘管啓迪醫療目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

瑞銀集團出售了 56,407 股啓迪醫療系統公司（Inspire Medical Systems, Inc.）的股票 $INSP